# A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

> **NCT02119819** · PHASE2 · COMPLETED · sponsor: **OPKO Health, Inc.** · enrollment: 420 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** LY2944876
- **DRUG:** Exenatide extended-release
- **DRUG:** Placebo
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT02119819
- **Lead sponsor:** OPKO Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-08
- **Final completion:** 2015-10
- **Target enrollment:** 420 (ACTUAL)
- **Last updated:** 2021-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02119819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02119819, "A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02119819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*